CAPRELSA® (vandetanib) Update

July 27, 2015 — AstraZeneca announced that it has entered into a definitive agreement with Genzyme to sell and transfer CAPRELSA^®, indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients who have non-operable locally advanced or metastatic disease. 

Genzyme’s acquisition will ensure that CAPRELSA^® continues to be available for patients and benefits from further development by Genzyme as a company focused on rare diseases. 

AstraZeneca is committed to ensuring that patients continue to receive treatment throughout this transition. There will be no interruption in current and pending access to the drug. 

AstraZeneca continues to have ongoing research programs in thyroid cancers. 

Patients with questions about this transfer may contact the AstraZeneca Information Center by phone at 1-800-236-9933 (Monday - Friday 8 a.m. - 6 p.m. ET, excluding holidays).